Description
The Highly Galactosylated Anti-HBV (Tuvirumab), a biobetter antibody contains with a high level of galactosylation.
Antibody Indication
Hepatitis B reinfection in liver transplant patients
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced HBV antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
HBV
Alternative Names
Exbivirumab; hepex-b; 569658-80-6; 19.79.5; HbsAg; HBV; Major surface antigen
Genecards
6584
Involvement in Disease
Its related pathways are Integrin Pathway and Signaling by GPCR.
Related Pathways
Promotes spermatogenesis and ovulation by stimulating the testes and ovaries to synthesize steroids.
Function
Cancer antibody; Microbiology and Infectious Disease antibody
Field of research
1.Glycosylation at Asn50 2.Glycosylation from GlyConnect
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, λ
Antibody Clone
Tuvirumab
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human monoclonal antibody expressed in CHO binding to human Hepatitis B virus. Tuvirumab is a human monoclonal antibody for the treatment of patients with chronic hepatitis B.
Antibody Indication
Hepatitis B reinfection in liver transplant patients
Hepatitis B reinfection in liver transplant patients
